For research use only. Not for therapeutic Use.
AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor[1][2].
AGL-2263 (5 μM, for 1 h followed by insulin treatment for 24 h) inhibits IR and insulin could still induce phosphorylation of AKT and ERK1/2 after the IR inhibition[3].
| Catalog Number | R067020 |
| CAS Number | 638213-98-6 |
| Synonyms | (E)-2-(3,4-dihydroxybenzoyl)-3-(2-oxo-3H-1,3-benzoxazol-5-yl)prop-2-enenitrile |
| Molecular Formula | C17H10N2O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C17H10N2O5/c18-8-11(16(22)10-2-3-13(20)14(21)7-10)5-9-1-4-15-12(6-9)19-17(23)24-15/h1-7,20-21H,(H,19,23)/b11-5+ |
| InChIKey | IUGRBTCJEYEDIY-VZUCSPMQSA-N |
| SMILES | C1=CC2=C(C=C1C=C(C#N)C(=O)C3=CC(=C(C=C3)O)O)NC(=O)O2 |
| Reference | [1]. Li Y, et al. GDM-associated insulin deficiency hinders the dissociation of SERT from ERp44 and down-regulates placental 5-HT uptake. Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):E5697-705. [2]. Hua Zhang, et al. Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. Curr Biol. 2014 Nov 3;24(21):2501-8. [3]. Ying Han, et al. Insulin mitigates apoptosis of porcine follicular granulosa cells by downregulating BimEL. Reprod Biol. 2019 Sep;19(3):293-298. |
